Taysha Gene Therapies (TSHA) Competitors $3.14 -0.02 (-0.48%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSHA vs. HHH, CRNX, AMRX, APLS, HCM, TLX, SRRK, RARE, CNTA, and MORShould you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Howard Hughes (HHH), Crinetics Pharmaceuticals (CRNX), AMNEAL PHARMACEUTICALS (AMRX), Apellis Pharmaceuticals (APLS), HUTCHMED (HCM), Telix Pharmaceuticals (TLX), Scholar Rock (SRRK), Ultragenyx Pharmaceutical (RARE), Centessa Pharmaceuticals (CNTA), and MorphoSys (MOR). Taysha Gene Therapies vs. Its Competitors Howard Hughes Crinetics Pharmaceuticals AMNEAL PHARMACEUTICALS Apellis Pharmaceuticals HUTCHMED Telix Pharmaceuticals Scholar Rock Ultragenyx Pharmaceutical Centessa Pharmaceuticals MorphoSys Taysha Gene Therapies (NASDAQ:TSHA) and Howard Hughes (NYSE:HHH) are related companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Do analysts prefer TSHA or HHH? Taysha Gene Therapies currently has a consensus target price of $8.29, suggesting a potential upside of 164.30%. Howard Hughes has a consensus target price of $83.33, suggesting a potential upside of 5.53%. Given Taysha Gene Therapies' higher probable upside, equities research analysts plainly believe Taysha Gene Therapies is more favorable than Howard Hughes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Howard Hughes 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, TSHA or HHH? Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$8.10M105.61-$89.30M-$0.34-9.22Howard Hughes$1.75B2.68$200.55M$4.5717.28 Do institutionals and insiders believe in TSHA or HHH? 77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 93.8% of Howard Hughes shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by insiders. Comparatively, 48.0% of Howard Hughes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is TSHA or HHH more profitable? Howard Hughes has a net margin of 12.85% compared to Taysha Gene Therapies' net margin of -1,144.97%. Howard Hughes' return on equity of 10.51% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-1,144.97% -78.44% -44.82% Howard Hughes 12.85%10.51%3.15% Which has more risk and volatility, TSHA or HHH? Taysha Gene Therapies has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Howard Hughes has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Does the media favor TSHA or HHH? In the previous week, Howard Hughes had 2 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 6 mentions for Howard Hughes and 4 mentions for Taysha Gene Therapies. Howard Hughes' average media sentiment score of 1.22 beat Taysha Gene Therapies' score of 0.64 indicating that Howard Hughes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Howard Hughes 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryHoward Hughes beats Taysha Gene Therapies on 13 of the 16 factors compared between the two stocks. Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSHA vs. The Competition Export to ExcelMetricTaysha Gene TherapiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$855.21M$4.19B$5.65B$10.32BDividend YieldN/A1.31%5.68%4.61%P/E Ratio-9.2210.7275.6626.31Price / Sales105.6115.59521.00169.30Price / CashN/A7.1537.5661.52Price / Book8.963.4212.996.34Net Income-$89.30M-$134.23M$3.29B$270.94M7 Day Performance4.85%0.38%-0.03%0.29%1 Month Performance7.36%3.45%4.13%6.89%1 Year Performance55.97%41.44%69.08%29.31% Taysha Gene Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSHATaysha Gene Therapies2.2225 of 5 stars$3.14-0.5%$8.29+164.3%+52.9%$855.21M$8.10M-9.22180News CoveragePositive NewsHHHHoward Hughes2.4658 of 5 stars$81.89+0.4%$83.33+1.8%+3.1%$4.84B$1.75B17.92608Positive NewsAnalyst UpgradeCRNXCrinetics Pharmaceuticals3.6997 of 5 stars$33.77-0.7%$68.86+103.9%-29.4%$3.20B$1.04M-8.22210Analyst ForecastAMRXAMNEAL PHARMACEUTICALS3.1573 of 5 stars$9.79-2.1%$11.60+18.5%+15.0%$3.14B$2.79B979.988,100APLSApellis Pharmaceuticals4.1153 of 5 stars$24.39-1.9%$34.12+39.9%-26.0%$3.14B$781.37M-13.40770Positive NewsHCMHUTCHMED3.0258 of 5 stars$17.54-2.2%$28.00+59.6%-8.5%$3.13B$630.20M0.001,811Analyst DowngradeTLXTelix Pharmaceuticals3.9034 of 5 stars$9.51+3.3%$21.33+124.3%N/A$3.12B$516.72M0.00N/AAnalyst ForecastSRRKScholar Rock4.4041 of 5 stars$33.67+6.3%$46.33+37.6%+290.3%$3.04B$33.19M-11.57140Trending NewsAnalyst ForecastInsider TradeOptions VolumeAnalyst RevisionRAREUltragenyx Pharmaceutical4.209 of 5 stars$29.00-4.3%$81.50+181.0%-50.0%$2.92B$560.23M-5.241,294Positive NewsCNTACentessa Pharmaceuticals3.3702 of 5 stars$22.02+1.0%$32.70+48.5%+54.4%$2.92B$6.85M-12.30200Insider TradeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies HHH Alternatives CRNX Alternatives AMRX Alternatives APLS Alternatives HCM Alternatives TLX Alternatives SRRK Alternatives RARE Alternatives CNTA Alternatives MOR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSHA) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
